PHILADELPHIA, PA — March 3, 2026 — Leads & Copy — Medicus Pharma Ltd. (NASDAQ: MDCX) will participate in the 38th Annual Roth Conference, scheduled for March 22-24 in Dana Point, California.
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will engage in a Fireside Chat hosted by Jonathan Aschoff, Managing Director and Senior Research Analyst at Roth Capital Partners. The discussion will cover the company’s clinical development programs, with a focus on Skinject’s potential in treating Gorlin Syndrome.
Dr. Bokhari is also expected to highlight Medicus’s AI-enabled drug development strategy and partnering readiness. The Fireside Chat will be available via webcast to registered conference attendees.
Medicus executives will be available for one-on-one meetings with institutional investors and potential partners during the conference. Further details about the Roth Conference can be found at https://www.roth.com/conferences.
Key Medicus Pharma programs to be discussed include SkinJect™, a localized immuno-oncology product targeting non-melanoma skin diseases like basal cell carcinoma (BCC) and Gorlin Syndrome, which represents an ~$2 billion market. Also to be discussed is Teverelix®, a next-generation GnRH antagonist for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr), representing an ~$6 billion market.
Medicus’s strategic focus involves advancing programs through Phase 2 proof-of-concept and seeking licensing or strategic partnerships with pharmaceutical companies for late-stage development and commercialization.
Medicus Pharma Ltd. is focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets. The company is actively engaged in multiple countries across three continents.
SkinJect Inc., a wholly owned subsidiary, is focused on commercializing a non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch. A Phase 1 study (SKNJCT-001) completed in March 2021 demonstrated safety and tolerability. Two randomized, controlled, double-blind, multicenter clinical studies (SKNJCT-003) and (SKNJCT-004) are underway in the United States, Europe and the United Arab Emirates.
In August 2025, Medicus announced a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), concerning their shared mutual interest in development or commercial arrangement contemplated by the MoU.
Also in August 2025, Medicus completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist, as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Teverelix directly suppresses sex hormone production without an initial surge in testosterone levels, potentially reducing cardiovascular risks. It is formulated as a microcrystalline suspension for sustained release and a six-week dosing interval.
In October 2025, Medicus announced a collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome.
Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect under physician-supervised treatment protocols.
In November 2025, the company received regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. Approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC).
In December 2025, Medicus announced the completion of enrollment of 90 patients in the United States for the Phase 2 clinical study (SKNJCT-003). The company expects to secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.
Also in December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc. to collaborate on the development of an AI-driven clinical data analytics platform to support capital-efficient clinical development.
In February 2026, the company announced that it has received “study may proceed” clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC).
Medicus’ development strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization.
The Company continues to assemble decision-grade clinical and regulatory data packages across its portfolio to support this partnering-focused model.
Source: Medicus Pharma Ltd.
